Proteonomix, Inc. (PROT) Examines Licensing of Diabetes Stem Cell Technology
MOUNTAINSIDE, NJ--(Marketwire -10/17/11)- PROTEONOMIX, INC. (OTC.BB: PROT.OB - News), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that it has decided to examine the possibility of licensing its stem cell diabetes related technology to another company in light of continued progress toward its trial of UMK-121, its stem cell treatment for patients awaiting liver transplant to overcome End Stage Liver Disease ("ESLD").
Proteonomix, Inc. (PROT) Notes Progress Toward Clinical Trial of UMK-121
MOUNTAINSIDE, NJ--(Marketwire -09/28/11)- PROTEONOMIX, INC. (OTC.BB: PROT.OB - News), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that it has made substantial progress in arranging the clinical trial of its stem cell treatment for patients awaiting liver transplant to overcome End Stage Liver Disease ("ESLD").
Proteonomix (PROT) Senior Management Meets With Investment Community
MOUNTAINSIDE, NJ--(Marketwire -09/06/11)- PROTEONOMIX, INC. (OTC.BB: PROT.OB - News), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced that Michael Cohen, Chief Executive Officer of Proteonomix and Ian McNiece, the Company's Chief Scientific Officer met today with the team at Gilford Securities, the Company's Investment Banker, and Aegis Capital.
Proteonomix, Inc. (PROT) Notes Progress in Proteoderm Distribution and Advancement of UMK-121
MOUNTAINSIDE, NJ--(Marketwire -08/23/11)- PROTEONOMIX, INC. (OTC.BB: PROT.OB - News), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that it has made substantial progress in arranging the distribution of its Proteoderm line of cosmeceutical products.
MOUNTAINSIDE, NJ--(Marketwire -08/02/11)- PROTEONOMIX, INC. (OTC.BB: PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, is pleased to announce that they have engaged the services of Gilford Securities, Inc. for the purposes of assisting and advising the Company on enhancing shareholder value and perform investment banking services for Proteonomix.
Proteonomix, Inc. (PROT) Engages Investment Banking Firm
MOUNTAINSIDE, NJ--(Marketwire - 06/16/11) - PROTEONOMIX, INC. (OTC.BB:PROT - News), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that it has engaged the services of Bedminster Financial Group, Ltd. to provide investment banking services for the Company with a view to finding joint venture partners and/or strategic investments into one or more of its subsidiaries in order to advance the scientific and commercial development of the subsidiaries and the technologies possessed by the subsidiaries.
Proteonomix, Inc. (PROT) Animal Studies Confirms Potential Use of UMK-121.
MOUNTAINSIDE, NJ--(Marketwire - 05/23/11) - PROTEONOMIX, INC. (OTC.BB:PROT - News), a biotechnology company ("Proteonomix" or the "Company") focused on developing therapeutics based upon the use of human cells and their derivatives, is pleased to announce the results of animal studies involving the Company's UMK-121 technology.The pre-clinical studies were conducted in rodents and a large animal model to confirm the potential of the UMK-121 technology to mobilize Stromal Stem Cells ("SSCs") into the peripheral blood of animals, thereby making the SSCs available for therapeutic uses.
Proteonomix, Inc. (PROT) Updates Its Global Activities; Ian McNiece Joins Board of Directors.
MOUNTAINSIDE, NJ, Jan 03, 2011 (MARKETWIRE via COMTEX) -- PROTEONOMIX, INC. (OTCBB: PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, is pleased to provide an update on the Company's addition to its Board of Directors. Proteonomix, Inc. is pleased to announce that Ian McNiece has been appointed to the Proteonomix Board of Directors effective today.
